CASMA THERAPEUTICS
Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
CASMA THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2017-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.casmatx.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
108.87 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Abata Therapeutics
Abata Therapeutics is a biotech company.
BridGene Biosciences
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules.
Flare Therapeutics
Flare Therapeutics is a biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases.
Neuraptive Therapeutics
Neuraptive Therapeutics is a medical technology company bringing novel products to patients with peripheral nerve injuries.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Trefoil Therapeutics
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases.
Yumanity Therapeutics
Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Current Advisors List
Current Employees Featured
Founder
Investors List
Third Rock Ventures
Third Rock Ventures investment in Series B - Casma Therapeutics
The Column Group
The Column Group investment in Series B - Casma Therapeutics
Schroder Adveq
Schroder Adveq investment in Series B - Casma Therapeutics
Eventide
Eventide investment in Series B - Casma Therapeutics
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Casma Therapeutics
Third Rock Ventures
Third Rock Ventures investment in Series A - Casma Therapeutics
Official Site Inspections
http://www.casmatx.com
- Host name: 7.53.196.104.bc.googleusercontent.com
- IP address: 104.196.53.7
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Casma Therapeutics"
About us - Casma Therapeutics
About us. Founded in 2018 and headquartered in Cambridge, MA, our team of experts in molecular biology and drug discovery is developing a technology that reprograms the autophagy pathway to degrade disease targets.See details»
Casma Therapeutics - Reprogramming autophagy to โฆ
About Casma. Casma Therapeutics is developing novel cellular degradation approaches based on the autophagy pathway to initiate new target areas for drug discovery and development that will profoundly impact the lives of patients.See details»
Casma Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The โฆSee details»
Investors - Casma Therapeutics
Astellas Venture Management LLC (AVM) is the corporate venture capital organization dedicated to reinforcing Astellas to accomplish it's strategic goals. Astellas, the ultimate parent company of AVM, headquartered in Tokyo, is โฆSee details»
Casma Therapeutics - LinkedIn
We're excited to share that Casma Therapeutics, Inc., a pioneer in leveraging the autophagy/lysosomal system for groundbreaking medicines, is participating at the prestigious Gordon Research ...See details»
Casma - VentureRadar
Develops cellular degradation approaches based on autophagy pathway, aiming to discover new drug targets and impact patients' lives in oncology, inflammation, neurodegeneration, and โฆSee details»
Casma Therapeutics - Overview, News & Similar companies
Nov 14, 2022 Casma Therapeutics contact info: Phone number: (857) 777-4990 Website: www.casmatx.com What does Casma Therapeutics do? Casma Therapeutics is โฆSee details»
Casma Therapeutics - Craft
Casma Therapeutics is a biotechnology company harnessing the natural cellular process of autophagy to design new medicines. The Company uses several approaches to intervene at โฆSee details»
Casma Therapeutics Company Overview, Contact Details
Nov 15, 2022 [email protected]: 5%. [email protected]: [email protected]: 2%. See more formats. Frequently Asked Questions Where is Casma Therapeutics 's headquarters โฆSee details»
Casma Therapeutics - Work in biotech
Casma Therapeutics is harnessing the power of autophagy to bring cures to patients with serious diseases. The traditional pharma approach is to use drugs to inhibit the active site of a disease โฆSee details»
Our team - Casma Therapeutics
Andrea was the president of the European Society of Human Genetics and Council member of the European Molecular Biology Organization. He is a recipient of two consecutive Advanced Investigator Grants of the European โฆSee details»
Casma Therapeutics Announces CEO Transition - Business Wire
Jan 31, 2023 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today โฆSee details»
Casma Therapeutics Raises $46.0 M in Series C Funding
Nov 15, 2022 For more information, please visit Casmaโs new website, www.casmatx.com. Contacts. Colleen DeSimone SVP, Finance [email protected] 857-777-4990 Release โฆSee details»
Casma Therapeutics Appoints Nagesh Mahanthappa, Ph.D
Nov 17, 2020 For more information, please visit www.casmatx.com. Contacts. Investors and Media Courteney Backstrom Casma Therapeutics, Inc. [email protected] 857-777 โฆSee details»
Casma Therapeutics Raises $46.0 M in Series C Funding
CAMBRIDGE, Mass., November 15, 2022 โ Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the โฆSee details»
Casma Therapeutics Announces $50 Million Series B Financing
Sep 10, 2020 Investor Contact Courteney Backstrom Casma Therapeutics, Inc. [email protected] 857-777-4248 Media Contact Stephanie Simon Ten Bridge โฆSee details»
Casma Therapeutics Announces Addition of Sharon Tooze,
CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design...See details»
้้ | ๅๆฐ็ๆณ้่งฃไธๅฏๆ่ฏ้ถ็น๏ผๆฐ้่ท4600ไธ็พๅ ่่ต
Nov 26, 2022 ้่ฟ้ๆฉๆง้่งฃ็พ็ ็้ถๆ ๏ผCasmaๆๆ้ปๆญขๆ้่ฝฌๅค็ง่ฟ็คใ็็ใ็ฅ็ปๅๆงๅไปฃ่ฐข็ดไนฑ็ธๅ ณ็พ็ ็่ฟๅฑใๆไปฌๅพ้ซๅ ดๅฐๅฏนๆญคๆฌก็ๆ่ต่ ไปฌ่กจ็คบๆฌข่ฟ๏ผไปไปฌๆ่ฏๅฐไบๆไปฌ้ๅฏน โฆSee details»
Casma Therapeutics Strengthens Leadership Team with โฆ
Dec 12, 2018 Previously, she served in human resource roles at Neon Therapeutics, Inc., Daktari Diagnostics, Inc., and The RMR Group. Earlier in her career she was director of โฆSee details»
Casma Therapeutics Establishes Scientific Advisory Board with ...
CAMBRIDGE, Mass. โ March 26, 2019 โ Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the โฆSee details»